Combretastatin A1 phosphate_product_DataBase

Bioactivity	Combretastatin A1 phosphate (Oxi4503; CA1P; Combretastatin A1 diphosphate) is a potent vascular disruptive agent. Combretastatin A1 phosphate exerts anti-angiogenic effects on tumors. Combretastatin A1 phosphate has the potential for the research of pancreatic neuroendocrine tumors[1][2].
In Vivo	Combretastatin A1 phosphate (100 mg/kg; I.p.; once at day 16 post tumor induction) 显示出抗肿瘤活性，并对小鼠肿瘤发挥抗血管生成作用当与 Sunitinib (HY-10255A) 连用时[2]。 Animal Model:
Name	Combretastatin A1 phosphate
CAS	288847-35-8
Formula	C18H22O12P2
Molar Mass	492.31
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Reference	[1]. Patterson DM, et al. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res. 2012 Mar 1;18(5):1415-25. [2]. Nguyen L, et al. Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis. BMC Cancer. 2016 Jul 26;16:533.

PeptideDB